Xeophin

ICO Dates TBD

Description

Xeophin has devised a funding pathway to develop the XeRA-1 Therapeutic for Rheumatoid Arthritis, however this offering represents much more than stake in a promising pharmaceutical. Xeophins’ unique approach to Biotech funding can change the paradigm of how medicine is financed. Xeophin is tokenizing 50% of the future royalties generated by XeRA-1, allowing its’ token holders to fund, and benefit from its’ success. Our mission is to take our core technologies and drive them through our six step process. The outcome being a transaction-ready and IP protected technology portfolio, tokenized. From then on, Xeophin will undertake commercialization activities to achieve a significant royalty deal, delivering value to our XeRA-1 Token holders. Being backed by a physical asset, the XeRA-1 Arthritis Therapeutic, the XERA1 token can increase in value as milestones are hit on the road to commercialization. Once live, token holders will yield cash royalty payments, commensurate to XeRA-1s’ earnings.

General
ICO Dates
TBD
Whitelist / KYC
KYC & Whitelist
Country
Australia
Ticket
XERA
Token Type
ERC20
Available for Sale
Financial
Pre sale Price
1 XERA = 0.5 USD
ICO price
1 XERA = 1 USD
Accepting
BTC, ETH, Fiat
Tokens for sale
345,450,000
Bonuses
Round A Up to 50%

Round B Up to 20%

Pre-ICO Up to 10%

Team
Travis Molloy Bsc
EXECUTIVE CHAIRMAN
Troy Neilson
CHIEF EXECUTIVE OFFICER
Jason Yeates
Chief Executive Officer